SelectQuote heads into its fiscal fourth-quarter report with an unusual disconnect on display. The operating story has been quietly improving, but the stock has been crushed anyway, down more than 25% since the last earnings release while the S&P 500 climbed nearly 8%. That gap of over 33 percentage points is the real setup here, and it raises the central question for this report: does the market know something the numbers don't yet show, or has SelectQuote simply been caught in a broader selloff of small, leveraged names trading below a dollar?
Consensus calls for a loss of $0.15 per share on revenue of $375 million, which would represent year-over-year revenue growth of roughly 9% even as the bottom line remains negative. That's a step down from the June quarter's $0.15 per share profit and $430.9 million in revenue, though seasonality plays a role here since the June quarter includes the tail of Medicare Advantage annual enrollment activity that doesn't repeat in the September quarter. Management reaffirmed full-year revenue guidance of $1.61 billion to $1.71 billion after the last call, and with consensus sitting at $1.69 billion for the fiscal year, the Street is positioned comfortably within that range, closer to the upper half than the low end.
The more important test is whether the operational green shoots from the June quarter's call carry forward. That call marked a shift in tone after two consecutive guidance cuts. Management pointed to SelectRx swinging back to positive EBITDA, a resolved pharmacy reimbursement dispute that had been a $20 million annual headwind, and a favorable $14 million accounting adjustment to commissions receivable that flattered senior segment margins. The company reaffirmed its full-year EBITDA guidance of $90 million to $100 million rather than cutting again, which matters because that range is still well below the original $120 million to $150 million target set just two quarters earlier. This report needs to show that the SelectRx profitability improvement and the Olathe facility's efficiency gains are durable rather than a one-quarter blip, and that the healthcare services growth deceleration seen in the June quarter, down to single digits from 26% and 55% growth in prior periods, doesn't continue sliding further.
Management also flagged that some of the June quarter's Medicare Advantage approval-rate strength might have been pulled forward from the September quarter, which is exactly the period now being reported. If that pull-forward concern proves accurate, senior segment revenue and approved policy counts could look softer than the recent trend suggests, testing whether the accounting adjustment inflated expectations for what comes next.
Sentiment heading into this report is more optimistic than it was last quarter, with bullish readings rising to 19.1% from 12.5%, even as the stock has fallen sharply. That combination suggests some investors see the pullback as overdone relative to the operational trajectory, but it's a modest shift, not a dramatic reversal in expectations.
The technical picture reinforces the disconnect. Shares trade at $0.73, well below both the 200-day moving average of $1.07 and the post-earnings trading range high of $1.39 set after the last report. The stock is closer to its post-earnings low of $0.64, and the current range is roughly in line with the prior quarter's $0.56 to $1.36 band, suggesting the market hasn't found a new equilibrium since the June report.
The question this earnings report needs to answer is whether the reaffirmed guidance and improving SelectRx economics represent a genuine inflection or a temporary reprieve propped up by one-time items and favorable timing. A management team that flagged NYSE listing compliance as a concern last quarter doesn't have much room for another disappointment. Confirmation that healthcare services growth is stabilizing and that the positive commissions adjustment wasn't masking underlying softness would go a long way toward closing the gap between the stock price and the narrative management has been building.